Who
Robert N. Fried
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Niagen Bioscience; Director, Fluent; President & CEO, Ideation Acquisition.
In numbers
- Trades disclosed
- 61
- Buys
- 14
- Sells
- 1
- Bought
- $431K
- Sold
- $6,379
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 26 Nov 2007
- Last trade
- 30 Jun 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 8 Jul 2026 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code A | $2,9971,106 at $2.71 | filing |
| 30 Jun 2026filed 8 Jul 2026 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code A | $2,9971,106 at $2.71 | filing |
| 24 Apr 2026filed 27 Apr 2026 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $52K20,000 at $2.61 | filing |
| 24 Apr 2026filed 27 Apr 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 24 Apr 2026filed 27 Apr 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 24 Apr 2026filed 27 Apr 2026 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $52K20,000 at $2.61 | filing |
| 19 Feb 2026filed 24 Feb 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —503,937 at $0.00 | filing |
| 19 Feb 2026filed 24 Feb 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —503,937 at $0.00 | filing |
| 9 Apr 2025filed 9 Apr 2025 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —66,667 at $0.00 | filing |
| 9 Apr 2025filed 9 Apr 2025 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Code M | $220K66,667 at $3.30 | filing |
| 25 Feb 2025filed 27 Feb 2025 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,518,600 at $0.00 | filing |
| 12 Feb 2025filed 14 Feb 2025 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —492,278 at $0.00 | filing |
| 22 Feb 2024filed 23 Feb 2024 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —399,568 at $0.00 | filing |
| 31 May 2023filed 1 Jun 2023 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Bought | $9,9407,000 at $1.42 | filing |
| 15 Feb 2023filed 17 Feb 2023 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —306,366 at $0.00 | filing |
| 30 Sep 2022filed 3 Oct 2022 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Bought | $100K80,000 at $1.25 | filing |
| 16 Mar 2022filed 16 Mar 2022 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Bought | $54K25,000 at $2.16 | filing |
| 17 Feb 2022filed 22 Feb 2022 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —240,448 at $0.00 | filing |
| 13 May 2021filed 17 May 2021 | NAGE Niagen BiosciencePharmaceuticals | SEC FORM 4 Bought | $67K10,000 at $6.65 | filing |
| 15 Mar 2021filed 17 Mar 2021 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —55,921 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.